

Hindustan Unilever Limited Unilever House B D Sawant Marg Chakala, Andheri East Mumbai 400 099

Tel: +91 (22) 5043 3000 Web: www.hul.co.in CIN: L15140MH1933PLC002030

26th February, 2020

To,

The General Manager The Bombay Stock Exchange Limited Department of Corporate Services P.J. Towers, Dalal Street Mumbai- 400 001

This is with reference to your observation letter bearing reference no. DCS/AMAL/JR/R37/1404/2018-19 dated 15th February, 2019 regarding the Scheme of Amalgamation by way of merger by absorption among GlaxoSmithKline Consumer Healthcare Limited ("**Transferor Company**") and Hindustan Unilever Limited (the "**Company**") and their respective Shareholders and Creditors (the "**Scheme**").

We further refer to our disclosure dated November 06, 2019 wherein we had informed you that the Hon'ble National Company Law Tribunal, Mumbai Bench ("**Mumbai NCLT**"), had vide it's Order dated 24th September, 2019, sanctioned the aforesaid Scheme, and that such Order was subject to sanction of Scheme by the National Company Law Tribunal, Chandigarh Bench ("**Chandigarh NCLT**").

In this regard, we wish to inform you that the Scheme has now received the sanction of the Chandigarh NCLT. The effective date of the Scheme will be communicated to you upon being finalized by the Transferor Company and the Company, in accordance with the procedure specified under the Scheme approved by the Mumbai NCLT and Chandigarh NCLT.

For Hindustan Unilever Limited

Dev Bajpai Executive Director, Legal and Corporate Affairs and Company Secretary DIN : 00050516 / FCS: 3354



Enclosed: A/a